151 related articles for article (PubMed ID: 15234571)
1. Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice.
Shibuya K; Kuwaki T; Akahori H; Kato T; Miyazaki H
Leuk Res; 2004 Sep; 28(9):941-6. PubMed ID: 15234571
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral blood in mice.
Honda K; Takenaka K; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
Bone Marrow Transplant; 2001 Aug; 28(4):329-34. PubMed ID: 11571503
[TBL] [Abstract][Full Text] [Related]
3. Effect of PEG-recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on growth and differentiation of the HEL cell line.
Catani L; Gugliotta L; Motta M; Tazzari P; Baravelli S; Tura S
Haematologica; 1998 May; 83(5):385-91. PubMed ID: 9658720
[TBL] [Abstract][Full Text] [Related]
4. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
[TBL] [Abstract][Full Text] [Related]
5. In vivo effects of pegylated recombinant human megakaryocyte growth and development factor on hematopoiesis in normal mice.
Kabaya K; Akahori H; Shibuya K; Nitta Y; Ida M; Kusaka M; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):651-60. PubMed ID: 8948023
[TBL] [Abstract][Full Text] [Related]
6. Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice.
Kabaya K; Shibuya K; Torii Y; Nitta Y; Ida M; Akahori H; Kato T; Kusaka M; Miyazaki H
Bone Marrow Transplant; 1996 Dec; 18(6):1035-41. PubMed ID: 8971370
[TBL] [Abstract][Full Text] [Related]
7. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression.
Coleman D; Fairchild D; Schindler-Horvat J; Munyakazi L; Neumann TA
Toxicol Sci; 1998 Sep; 45(1):77-87. PubMed ID: 9848114
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic recovery following autologous bone marrow transplantation in a nonhuman primate: effect of variation in treatment schedule with PEG-rHuMGDF.
Farese AM; MacVittie TJ; Roskos L; Stead RB
Stem Cells; 2003; 21(1):79-89. PubMed ID: 12529554
[TBL] [Abstract][Full Text] [Related]
9. Early Australian clinical studies with pegylated recombinant human megakaryocyte growth and development factor.
Basser RL
Stem Cells; 1998; 16 Suppl 2():225-9. PubMed ID: 11012194
[TBL] [Abstract][Full Text] [Related]
10. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.
Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB
Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288
[TBL] [Abstract][Full Text] [Related]
11. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia--a randomized, placebo-controlled, double-blind safety and efficacy study.
Geissler K; Yin JA; Ganser A; Sanz MA; Szer J; Raghavachar A; Hoelzer D; Martinez C; Taylor K; Kanz L; To LB; Archimbaud E
Ann Hematol; 2003 Nov; 82(11):677-83. PubMed ID: 14530872
[TBL] [Abstract][Full Text] [Related]
12. An analysis of the effects of combined treatment with rmGM-CSF and PEG-rHuMGDF in murine bone marrow transplant recipients.
Molineux G; Hartley C; McElroy P; McCrea C; Kerzic P; McNiece I
Stem Cells; 1997; 15(1):43-9. PubMed ID: 9007221
[TBL] [Abstract][Full Text] [Related]
13. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
14. [Study of thrombopoietin and its receptor C-mpl in acute leukemia].
Guo Y; Bian S; Luo M
Zhonghua Xue Ye Xue Za Zhi; 1999 Mar; 20(3):120-3. PubMed ID: 11601235
[TBL] [Abstract][Full Text] [Related]
15. Treatment of the Kasabach-Merritt syndrome with pegylated recombinant human megakaryocyte growth and development factor in mice: elevated platelet counts, prolonged survival, and tumor growth inhibition.
Verheul HM; Panigrahy D; Flynn E; Pinedo HM; D'Amato RJ
Pediatr Res; 1999 Nov; 46(5):562-5. PubMed ID: 10541319
[TBL] [Abstract][Full Text] [Related]
16. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice.
Shibuya K; Akahori H; Takahashi K; Tahara E; Kato T; Miyazaki H
Blood; 1998 Jan; 91(1):37-45. PubMed ID: 9414267
[TBL] [Abstract][Full Text] [Related]
17. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.
Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG
Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381
[TBL] [Abstract][Full Text] [Related]
19. Development of thrombopoietin receptor agonists for clinical use.
Ikeda Y; Miyakawa Y
J Thromb Haemost; 2009 Jul; 7 Suppl 1():239-44. PubMed ID: 19630808
[TBL] [Abstract][Full Text] [Related]
20. Overview of the safety and biologic effects of PEG-rHuMGDF in clinical trials.
Sheridan W; Menchaca D
Stem Cells; 1998; 16 Suppl 2():193-8. PubMed ID: 11012191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]